Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate for CMV in Stem Cell Transplant Recipients
NCT00284687Phase 3Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Jul 2006
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of artesunate in cytomegalovirus infection (CMV), sponsored by Hadassah Medical Organization. Primary endpoints: Safety at 60 days and Efficacy at 60 days. Started Jul 2006; status: completed.
02
Drugs
artesunate
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00284687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00284687.